TLDR:
- European biotech investment landscape is explored on “The Top Line” podcast.
- Maina Bhaman, a Partner at Sofinnova Capital Strategy, provides insights into how investors are approaching the European biotech sector.
Summary:
On the “The Top Line” podcast, Fierce Biotech’s James Waldron interviews Maina Bhaman, a Partner at Sofinnova Capital Strategy, to discuss the European biotech investment landscape in 2024. Bhaman provides insights into how investors are approaching the sector and highlights the strong fundamentals that are attracting investors to European biotech companies.
Bhaman mentions that there is optimism in the industry, especially at conferences, but cautions that a boost in biotech IPOs may not be imminent. Despite this, investors are staying loyal to European biotech companies due to the positive outlook for the sector.
